Findabis: The UK Canna-Tech Play Hiding in Plain Sight

Findabis is currently pre-launch; its public site shows the “Launching soon” page.

The problem: a fragmented, regulated market

Medical cannabis has been legal on prescription in the UK since 1 November 2018. But legal did not mean unified. Only a specialist doctor can start a prescription, almost all patients are treated privately, and patients, clinics, pharmacies, suppliers and brands have been working across disconnected systems.

That is the gap Findabis is building into. Its public face is still quiet: findabis.com currently shows a “Launching soon” page promising a guide to clinics, pharmacies and products. Behind that page, the scope is much wider.

The platform is designed to put the different sides of the UK medical cannabis system onto one stack. That means patient discovery at the front, but also clinic administration, pharmacy stock and dispensing, supplier allocation and controlled access to product information further down the chain.

For a sector shaped as much by process as presentation, that distinction matters. The homepage may still be hidden in the shadows. The infrastructure underneath is already visible.

What Findabis built, layer by layer

Start with patients. Findabis is building a directory of clinics and pharmacies across England, Scotland, Wales and Northern Ireland, alongside a free eligibility check.

The check does not produce a score. It returns one of three outcomes: likely eligible, needs a clinician’s review, or not eligible. It is a guide rather than a diagnosis, and nothing is shared with a clinic until the patient chooses one.

The Findabis eligibility check returns one of three outcomes, not a score. It is a guide, not a diagnosis.

The public product layer is deliberately limited. Visitors see only bare product facts. Stock information and per-pharmacy prices are shown only to verified patients and professionals.

The clinic layer goes deeper. Clinics can run their own websites and white-label patient portals on Findabis, with eligibility triage, consultations, prescriptions, fees and memberships. The system also covers team management, including checks on doctors’ registrations, plus signed and dated records of multi-disciplinary team reviews.

For pharmacies, Findabis includes stock and batch tracking with expiry dates, dispensing labels, prescription-allowance checks and Royal Mail shipping.

For suppliers, there is a wholesale marketplace with reservations and earliest-expiry-first allocation.

There is an education layer too. Findabis has explorable 3D spaces about strains, clinics and suppliers in beta.

Taken together, this is less a single consumer website than a collection of linked operating layers. The public sees the front door. Clinics, pharmacies and suppliers get the machinery behind it.

Proof it works: the companies already running on it

This is where the “Launching soon” page starts to look almost like camouflage. Findabis is pre-launch to the public, yet live company websites are already running on the platform.

The clearest before-and-after is The Plug Medical Group, a pain specialist clinic on Harley Street. Its old website could only take an enquiry, with costs coming after approval. Its new Findabis site has a free online eligibility check and published fees, and the clinic is waiting on a new patient portal from Findabis.

On its own website, The Plug Medical Group says it is backing Findabis as the key platform for medical cannabis patients in the UK. That is the clinic’s own stated position, not an external endorsement.

The Plug Medical Group’s live Findabis website on Harley Street.

Classix Medical also has a live website running on Findabis.

Classix Medical is among the live websites already running on Findabis.

Medicus is live on the platform too. It is a UK flower brand made with Cantourage.

Medicus, a UK flower brand made with Cantourage, is already running on Findabis.

Cali-X, a Los Angeles genetics brand, is also running a live Findabis website.

Cali-X, a Los Angeles genetics brand, is also running on Findabis.

The significance is not a claim about scale. No user numbers, revenue figures or market-share data have been supplied. What is visible is breadth: different types of company are already using Findabis before the main public launch.

Why traders should keep it on their radar

For Leviathan readers, this is not a quoted-security story. Findabis is privately held and not listed. There is no public share price attached to any of this, and nothing here is an offer of shares.

What is worth watching is execution.

Findabis reaches from patient triage into clinic administration, regulated records, pharmacy fulfilment and supplier-side allocation. Those are different workflows with different users and different constraints. The test is whether one software layer can keep working across them as the public-facing platform comes online.

There are already some concrete markers. Live websites are running on the stack. The Plug Medical Group moved from an enquiry-only site to a Findabis build with a free eligibility check and published fees, with a patient portal still to come. Product information is separated by user status, with stock and per-pharmacy pricing restricted to verified patients and professionals.

The compliance choices are part of the product architecture rather than an afterthought. The eligibility check is framed as guidance rather than diagnosis. Patient information is not passed to a clinic until the patient chooses one. Clinic tooling includes checks on doctors’ registrations and signed, dated MDT records. Pharmacy functions include prescription-allowance checks alongside stock and batch controls.

None of that proves future commercial success. It does show what the company is actually attempting to solve: the connective tissue between multiple participants in a regulated private-care market.

That makes Findabis one to watch. The public brand is still pre-launch. The operating footprint is not.

What to watch next

The obvious milestone is the public launch:

Beyond that, there are several execution points already visible from the supplied information. The Plug Medical Group is waiting on its new patient portal. Findabis has its 3D education spaces in beta. The platform is also positioning patient discovery, clinic operations, pharmacy workflows and supplier allocation as parts of the same system.

The question is not whether the landing page looks finished. It is whether those layers continue to connect cleanly as more of Findabis becomes public.

For now, findabis.com remains the page to watch. It still says “Launching soon”. The interesting part is how much is already running behind it.

FAQ

What is Findabis?

Findabis is a UK medical cannabis platform designed to put patients, clinics, pharmacies, suppliers and brands on one system. The public layer includes clinic and pharmacy directories and a free eligibility check. Behind that sit tools for clinic workflows, pharmacy stock and dispensing, and supplier wholesale allocation. It is currently pre-launch to the public.

Is it live yet?

Findabis is pre-launch, and findabis.com currently shows a “Launching soon” page. Parts of the platform are already in use through live company websites.

Who is it for?

Findabis is built for patients, clinics, pharmacies, suppliers and brands. Patients get discovery tools and an eligibility check. Clinics get websites, portals and workflow tools. Pharmacies get inventory, dispensing and shipping functions. Suppliers get a wholesale marketplace with reservations and earliest-expiry-first allocation.

How does the eligibility check work?

The free check returns one of three outcomes: likely eligible, needs a clinician’s review, or not eligible. It is not a score or a diagnosis. Nothing is shared with a clinic until the patient chooses one, and the tool does not replace the specialist doctor who can start a prescription.

Which companies use it?

Live websites already running on Findabis include The Plug Medical Group and Cantourage UK. Classix Medical also has a live site on the platform. Medicus, a UK flower brand made with Cantourage, is another. Cali-X, a Los Angeles genetics brand, is also running on it.

How does it handle UK rules?

Findabis builds restrictions into the product. The public sees only bare product facts, while stock and per-pharmacy prices are shown only to verified patients and professionals. Clinic tools include checks on doctors’ registrations and signed, dated MDT review records. The eligibility check is a guide, not a diagnosis, and only a specialist doctor can start a prescription.

Is Findabis a public company / can I invest?

Findabis is privately held and not listed. This article is not an offer of shares and does not provide any route to acquire an interest in the company. The coverage here is about sector and execution: the platform, the workflows it connects and the live websites already running on it.